2022
Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
del Mar Castro M, Cossio A, Navas A, Fernandez O, Valderrama L, Cuervo-Pardo L, Marquez-Oñate R, Gómez MA, Saravia NG. Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia. Pathogens 2022, 11: 378. PMID: 35335703, PMCID: PMC8949591, DOI: 10.3390/pathogens11030378.Peer-Reviewed Original ResearchAddition of pentoxifyllinePeripheral blood mononuclear cellsMeglumine antimoniate treatmentPlacebo-controlled trialCutaneous leishmaniasis patientsBlood mononuclear cellsInflammatory gene expressionAntimoniate treatmentOral pentoxifyllineTrial patientsAdverse eventsInflammatory mediatorsMucosal leishmaniasisLeishmaniasis patientsAntimonial treatmentClinical benefitMononuclear cellsStandard treatmentMultiple lesionsTherapeutic failureTherapeutic responseClinical trialsFailure rateStudy groupSingle lesion
2003
Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002.
González IJ, Padilla JO, Giraldo LE, Saravia NG. Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002. Biomédica 2003, 23: 38-46. PMID: 12696398, DOI: 10.7705/biomedica.v23i1.1196.Peer-Reviewed Original ResearchConceptsSulfadoxine/pyrimethamineTreatment failureUncomplicated Plasmodium falciparum malariaCombination of amodiaquineEfficacy of amodiaquinePlasmodium falciparum malariaSP treatment failureModerate malaria transmissionAntimalarial drug resistanceTreatment of malariaFalciparum malariaAntimalarial treatmentTherapeutic failureAntimalarial resistanceCurrent doseAntimalarial efficacyMalaria transmissionPatientsAntimalarial drugsDrug resistanceAmodiaquinePlasmodium falciparumTreatment regimesMalariaEfficacy